These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 26716505

  • 1. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
    Yin DT, Xu J, Lei M, Li H, Wang Y, Liu Z, Zhou Y, Xing M.
    Oncotarget; 2016 Feb 02; 7(5):5830-41. PubMed ID: 26716505
    [Abstract] [Full Text] [Related]

  • 2. [Expression of CCDC67 mRNA and its role in patients with papillary thyroid carcinoma].
    Yin D, Xu J, Wang Y, Li H, Zhang Y, Jiang J, Wang Q.
    Zhonghua Yi Xue Za Zhi; 2014 Aug 13; 94(30):2382-5. PubMed ID: 25399985
    [Abstract] [Full Text] [Related]

  • 3. Osteopontin levels in patients with papillary thyroid cancer according to the presence of Hashimoto's thyroiditis.
    Park SH, Park CS, Kim YI, Nam-Goong IS, Kim YS, Lee JC, Choi JI, Park JW, Kim ES.
    Asian Pac J Cancer Prev; 2015 Aug 13; 16(6):2447-51. PubMed ID: 25824779
    [Abstract] [Full Text] [Related]

  • 4. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
    Liao T, Qu N, Shi RL, Guo K, Ma B, Cao YM, Xiang J, Lu ZW, Zhu YX, Li DS, Ji QH.
    Oncotarget; 2017 Jan 03; 8(1):238-247. PubMed ID: 27462868
    [Abstract] [Full Text] [Related]

  • 5. MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67.
    Liu ZM, Wu ZY, Li WH, Wang LQ, Wan JN, Zhong Y.
    Eur Rev Med Pharmacol Sci; 2019 Apr 03; 23(8):3421-3430. PubMed ID: 31081096
    [Abstract] [Full Text] [Related]

  • 6. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
    Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, Kang HY, Liu RT.
    J Clin Endocrinol Metab; 2013 Feb 03; 98(2):E196-205. PubMed ID: 23264400
    [Abstract] [Full Text] [Related]

  • 7. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
    Nicolussi A, D'Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C, Di Gioia C, Nardi F, Giannini G, Coppa A.
    Int J Oncol; 2014 Feb 03; 44(2):548-56. PubMed ID: 24316730
    [Abstract] [Full Text] [Related]

  • 8. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
    Liu YM, Ying SP, Huang YR, Pan Y, Chen WJ, Ni LQ, Xu JY, Shen QY, Liang Y.
    World J Surg Oncol; 2016 Feb 04; 14(1):30. PubMed ID: 26846782
    [Abstract] [Full Text] [Related]

  • 9. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM, Gu J, Zhang YS, Wei WJ, Qu N, Wen D, Liao T, Shi RL, Zhang L, Ji QH, Wang Y, Sun GH, Zhao YX, Wang YJ, Yu J, Zhu YX.
    Oncol Rep; 2018 Jan 04; 39(1):338-348. PubMed ID: 29115628
    [Abstract] [Full Text] [Related]

  • 10. A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.
    Occhi G, Barollo S, Regazzo D, Bertazza L, Galuppini F, Guzzardo V, Jaffrain-Rea ML, Vianello F, Ciato D, Ceccato F, Watutantrige-Fernando S, Bisognin A, Bortoluzzi S, Pennelli G, Boscaro M, Scaroni C, Mian C.
    Oncotarget; 2015 Oct 13; 6(31):32104-14. PubMed ID: 26392334
    [Abstract] [Full Text] [Related]

  • 11. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
    Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, Condouris S, Tallini G, Westra WH, Umbricht CB, Zeiger MA, Califano JA, Vasko V, Xing M.
    Int J Cancer; 2006 Nov 15; 119(10):2322-9. PubMed ID: 16858683
    [Abstract] [Full Text] [Related]

  • 12. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T, Shen X, Liu R, Zhu G, Bishop J, Xing M.
    Oncotarget; 2017 Jan 03; 8(1):900-914. PubMed ID: 27863429
    [Abstract] [Full Text] [Related]

  • 13. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
    Feng C, Gao Y, Wang C, Yu X, Zhang W, Guan H, Shan Z, Teng W.
    J Clin Endocrinol Metab; 2013 Sep 03; 98(9):E1524-33. PubMed ID: 23846818
    [Abstract] [Full Text] [Related]

  • 14. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L.
    Eur J Endocrinol; 2013 May 03; 168(5):675-81. PubMed ID: 23416953
    [Abstract] [Full Text] [Related]

  • 15. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
    Pasquali D, Santoro A, Bufo P, Conzo G, Deery WJ, Renzullo A, Accardo G, Sacco V, Bellastella A, Pannone G.
    Thyroid; 2011 Apr 03; 21(4):391-9. PubMed ID: 21385081
    [Abstract] [Full Text] [Related]

  • 16. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.
    Cancer Cytopathol; 2015 Oct 03; 123(10):593-602. PubMed ID: 26230187
    [Abstract] [Full Text] [Related]

  • 17. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G, Mikhno N, Khabalova T, Svyatchenko S, Mostovich L, Shevchenko S, Gulyaeva L.
    Surg Oncol; 2018 Dec 03; 27(4):702-708. PubMed ID: 30449496
    [Abstract] [Full Text] [Related]

  • 18. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
    Zhang X, Li D, Li M, Ye M, Ding L, Cai H, Fu D, Lv Z.
    Int J Cancer; 2014 Jan 15; 134(2):257-67. PubMed ID: 23457043
    [Abstract] [Full Text] [Related]

  • 19. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.
    Cancer Res; 2009 Nov 01; 69(21):8317-25. PubMed ID: 19861538
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.